Skip to main content
SpringerLink
Log in

Hereditary Medullary Thyroid Cancer Genotype–Phenotype Correlation

  • Chapter
  • First Online:
Medullary Thyroid Carcinoma

Part of the book series: Recent Results in Cancer Research ((RECENTCANCER,volume 204))

Abstract

During the last two decades, there has been a marked expansion of our knowledge of both the basic and clinical aspects of multiple endocrine neoplasia type 2 (MEN2). There are two clinically distinct types of MEN2 syndrome, termed MEN2A and MEN2B. Within MEN2A, there are four variants: (i) classical MEN2A, represented by the uniform presence of MTC and the less frequent occurrence of pheochromocytoma, or primary hyperparathyroidism, or both; (ii) MEN2A with cutaneous lichen amyloidosis; (iii) MEN2A with Hirschsprung’s disease; and (iv) familial medullary thyroid carcinoma (FMTC), i.e., families or individuals with only MTC. MEN2B is associated with MTC, pheochromocytoma, and mucosal neuromas. Hereditary MTC is caused by autosomal dominant gain of function mutations in the RET proto-oncogene. Specific RET mutations may suggest a predilection toward a particular phenotype and clinical course with a strong genotype–phenotype correlation. Based upon these genotype–phenotype correlations, RET mutations are now stratified into three risk levels, i.e., highest, high, and moderate risk, based on the penetrance and aggressiveness of the MTC. Children in the highest risk category should undergo thyroidectomy in their first year of life, and perhaps even in their first months of life. Children in the high-risk category should have ultrasound of the neck and calcitonin (CTN) measurement performed prior to thyroidectomy. Thyroidectomy should typically be performed at the age of 5 or earlier, depending on the presence of elevated serum CTN levels. However, heterogeneity in disease expression and progression within these groups varies considerably. To personalize disease management, the decision regarding the age of prophylactic thyroidectomy is no longer based upon genotype alone but is currently driven by additional clinical data, the most important being serum CTN levels; specifically, the decision to perform thyroidectomy should err on the safe side if the CTN level is elevated but below 30 pg/ml, especially in the moderate risk group. Personalized management also includes decisions about the best age to begin biochemical screening for pheochromocytoma and primary hyperparathyroidism.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Similar content being viewed by others

Abbreviations

MTC:

Medullary thyroid carcinoma

MEN:

Multiple endocrine neoplasia

FMTC:

Familial medullary thyroid carcinoma

CTN:

Calcitonin

PHPT:

Primary hyperparathyroidism

CCH:

C-cell hyperplasia

References

  • Asai N, Jijiwa M, Enomoto A, Kawai K, Maeda K, Ichiahara M et al (2006) RET receptor signaling: dysfunction in thyroid cancer and Hirschsprung’s disease. Pathol Int 56(4):164–172

    Article  CAS  PubMed  Google Scholar 

  • Barbet J, Campion L, Kraeber-Bodere F, Chatal JF, Group GTES (2005) Prognostic impact of serum calcitonin and carcinoembryonic antigen doubling-times in patients with medullary thyroid carcinoma. J Clin Endocrinol Metab 90(11):6077–6084

    Article  CAS  PubMed  Google Scholar 

  • Basuyau JP, Mallet E, Leroy M, Brunelle P (2004) Reference intervals for serum calcitonin in men, women, and children. Clin Chem 50(10):1828–1830

    Article  CAS  PubMed  Google Scholar 

  • Berndt I, Reuter M, Saller B, Frank-Raue K, Groth P, Grussendorf M et al (1998) A new hot spot for mutations in the ret protooncogene causing familial medullary thyroid carcinoma and multiple endocrine neoplasia type 2A. J Clin Endocrinol Metab 83(3):770–774

    CAS  PubMed  Google Scholar 

  • Bethanis S, Koutsodontis G, Palouka T, Avgoustis C, Yannoukakos D, Bei T et al (2007) A newly detected mutation of the RET protooncogene in exon 8 as a cause of multiple endocrine neoplasia type 2A. Hormones 6(2):152–156

    Article  PubMed  Google Scholar 

  • Brandi ML, Gagel RF, Angeli A, Bilezikian JP, Beck-Peccoz P, Bordi C et al (2001) Guidelines for diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 86(12):5658–5671

    Article  CAS  PubMed  Google Scholar 

  • Brauckhoff M, Machens A, Hess S, Lorenz K, Gimm O, Brauckhoff K et al (2008) Premonitory symptoms preceding metastatic medullary thyroid cancer in MEN 2B: an exploratory analysis. Surgery 144(6):1044–1050 discussion 50–3

    Article  PubMed  Google Scholar 

  • Brauckhoff M, Machens A, Lorenz K, Bjoro T, Varhaug JE, Dralle H (2014) Surgical curability of medullary thyroid cancer in multiple endocrine neoplasia 2B: a changing perspective. Ann Surg 259(4):800–806

    Article  PubMed  Google Scholar 

  • Carlson KM, Bracamontes J, Jackson CE, Clark R, Lacroix A, Wells SA Jr et al (1994) Parent-of-origin effects in multiple endocrine neoplasia type 2B. Am J Hum Genet 55(6):1076–1082

    PubMed Central  CAS  PubMed  Google Scholar 

  • Ceccherini I, Romei C, Barone V, Pacini F, Martino E, Loviselli A et al (1994) Identification of the Cys634→Tyr mutation of the RET proto-oncogene in a pedigree with multiple endocrine neoplasia type 2A and localized cutaneous lichen amyloidosis. J Endocrinol Invest 17(3):201–204

    Article  CAS  PubMed  Google Scholar 

  • Cosci B, Vivaldi A, Romei C, Gemignani F, Landi S, Ciampi R et al (2011) In silico and in vitro analysis of rare germline allelic variants of RET oncogene associated with medullary thyroid cancer. Endocr Relat Cancer 18(5):603–612

    Article  CAS  PubMed  Google Scholar 

  • Cranston AN, Carniti C, Oakhill K, Radzio-Andzelm E, Stone EA, McCallion AS et al (2006) RET is constitutively activated by novel tandem mutations that alter the active site resulting in multiple endocrine neoplasia type 2B. Cancer Res 66(20):10179–10187

    Article  CAS  PubMed  Google Scholar 

  • Crockett DK, Piccolo SR, Ridge PG, Margraf RL, Lyon E, Williams MS et al (2011) Predicting phenotypic severity of uncertain gene variants in the RET proto-oncogene. PLoS ONE 6(3):e18380

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Da Silva AM, Maciel RM, Da Silva MR, Toledo SR, De Carvalho MB, Cerutti JM (2003) A novel germ-line point mutation in RET exon 8 (Gly(533)Cys) in a large kindred with familial medullary thyroid carcinoma. J Clin Endocrinol Metab 88(11):5438–5443

    Article  PubMed  Google Scholar 

  • Donis-Keller H, Dou S, Chi D, Carlson KM, Toshima K, Lairmore TC et al (1993) Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet 2(7):851–856

    Article  CAS  PubMed  Google Scholar 

  • Eisenhofer G, Lenders JW, Goldstein DS, Mannelli M, Csako G, Walther MM et al (2005) Pheochromocytoma catecholamine phenotypes and prediction of tumor size and location by use of plasma free metanephrines. Clin Chem 51(4):735–744

    Article  CAS  PubMed  Google Scholar 

  • Elisei R, Romei C, Cosci B, Agate L, Bottici V, Molinaro E et al (2007) RET genetic screening in patients with medullary thyroid cancer and their relatives: experience with 807 individuals at one center. J Clin Endocrinol Metab 92(12):4725–4729

    Article  CAS  PubMed  Google Scholar 

  • Elisei R, Romei C, Renzini G, Bottici V, Cosci B, Molinaro E et al (2012) The timing of total thyroidectomy in RET gene mutation carriers could be personalized and safely planned on the basis of serum calcitonin: 18 years experience at one single center. J Clinical Endocrinol Metab 97(2):426–435

    Article  CAS  Google Scholar 

  • Elisei R, Alevizaki M, Conte-Devolx B, Frank-Raue K, Leite V, Williams GR (2013) 2012 European thyroid association guidelines for genetic testing and its clinical consequences in medullary thyroid cancer. Eur Thyroid J 1(4):216–231

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Eng C, Clayton D, Schuffenecker I, Lenoir G, Cote G, Gagel RF et al (1996) The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. Int RET Mutat Consortium Anal JAMA 276(19):1575–1579

    CAS  Google Scholar 

  • Erlic Z, Hoffmann MM, Sullivan M, Franke G, Peczkowska M, Harsch I et al (2010) Pathogenicity of DNA variants and double mutations in multiple endocrine neoplasia type 2 and von Hippel-Lindau syndrome. J Clin Endocrinol Metab 95(1):308–313

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Frank-Raue K, Hoppner W, Frilling A, Kotzerke J, Dralle H, Haase R et al (1996) Mutations of the ret protooncogene in German multiple endocrine neoplasia families: relation between genotype and phenotype. German Medullary Thyroid Carcinoma Study Group. J Clin Endocrinol Metab 81(5):1780–1783

    CAS  PubMed  Google Scholar 

  • Frank-Raue K, Buhr H, Dralle H, Klar E, Senninger N, Weber T et al (2006) Long-term outcome in 46 gene carriers of hereditary medullary thyroid carcinoma after prophylactic thyroidectomy: impact of individual RET genotype. Eur J Endocrinol Eur Fed Endocr Soc 155(2):229–236

    Article  CAS  Google Scholar 

  • Frank-Raue K, Rondot S, Schulze E, Raue F (2007) Change in the spectrum of RET mutations diagnosed between 1994 and 2006. Clin Lab 53(5–6):273–282

    CAS  PubMed  Google Scholar 

  • Frank-Raue K, Machens A, Scheuba C, Niederle B, Dralle H, Raue F et al (2008) Difference in development of medullary thyroid carcinoma among carriers of RET mutations in codons 790 and 791. Clin Endocrinol 69(2):259–263

    Article  CAS  Google Scholar 

  • Frank-Raue K, Rybicki LA, Erlic Z, Schweizer H, Winter A, Milos I et al (2011) Risk profiles and penetrance estimations in multiple endocrine neoplasia type 2A caused by germline RET mutations located in exon 10. Hum Mutat 32(1):51–58

    Article  CAS  PubMed  Google Scholar 

  • Gagel RF, Levy ML, Donovan DT, Alford BR, Wheeler T, Tschen JA (1989) Multiple endocrine neoplasia type 2a associated with cutaneous lichen amyloidosis. Ann Intern Med 111(10):802–806

    Article  CAS  PubMed  Google Scholar 

  • Gimm O, Niederle BE, Weber T, Bockhorn M, Ukkat J, Brauckhoff M et al (2002) RET proto-oncogene mutations affecting codon 790/791: a mild form of multiple endocrine neoplasia type 2A syndrome? Surgery 132(6):952–959 discussion 9

    Article  PubMed  Google Scholar 

  • Ilias I, Pacak K (2004) Current approaches and recommended algorithm for the diagnostic localization of pheochromocytoma. J Clin Endocrinol Metab 89(2):479–491

    Article  CAS  PubMed  Google Scholar 

  • Jasim S, Ying AK, Waguespack SG, Rich TA, Grubbs EG, Jimenez C et al (2011) Multiple endocrine neoplasia type 2B with a RET proto-oncogene A883F mutation displays a more indolent form of medullary thyroid carcinoma compared with a RET M918T mutation. Thyroid 21(2):189–192 (official journal of the American Thyroid Association)

    Google Scholar 

  • Kaldrymides P, Mytakidis N, Anagnostopoulos T, Vassiliou M, Tertipi A, Zahariou M et al (2006) A rare RET gene exon 8 mutation is found in two Greek kindreds with familial medullary thyroid carcinoma: implications for screening. Clin Endocrinol 64(5):561–566

    Article  CAS  Google Scholar 

  • Kraimps JL, Denizot A, Carnaille B, Henry JF, Proye C, Bacourt F et al (1996) Primary hyperparathyroidism in multiple endocrine neoplasia type IIa: retrospective French multicentric study. Groupe d’Etude des Tumeurs a Calcitonine (GETC, French Calcitonin Tumors Study Group), French Association of Endocrine Surgeons. World J Surg 20(7):808–812 (discussion 12–3)

    Google Scholar 

  • Kloos RT, Eng C, Evans DB, Francis GL, Gagel RF, et al American Thyroid Association Guidelines Task F (2009) Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 19(6):565–612 (official journal of the American Thyroid Association)

    Google Scholar 

  • Machens A, Niccoli-Sire P, Hoegel J, Frank-Raue K, van Vroonhoven TJ, Roeher HD et al (2003) Early malignant progression of hereditary medullary thyroid cancer. N Engl J Med 349(16):1517–1525

    Article  CAS  PubMed  Google Scholar 

  • Machens A, Lorenz K, Dralle H (2009) Individualization of lymph node dissection in RET (rearranged during transfection) carriers at risk for medullary thyroid cancer: value of pretherapeutic calcitonin levels. Ann Surg 250(2):305–310

    Article  PubMed  Google Scholar 

  • Margraf RL, Crockett DK, Krautscheid PM, Seamons R, Calderon FR, Wittwer CT et al (2009) Multiple endocrine neoplasia type 2 RET protooncogene database: repository of MEN2-associated RET sequence variation and reference for genotype/phenotype correlations. Hum Mutat 30(4):548–556

    Article  CAS  PubMed  Google Scholar 

  • Mathew CG, Chin KS, Easton DF, Thorpe K, Carter C, Liou GI et al (1987) A linked genetic marker for multiple endocrine neoplasia type 2A on chromosome 10. Nature 328(6130):527–528

    Article  CAS  PubMed  Google Scholar 

  • Menko FH, van der Luijt RB, de Valk IA, Toorians AW, Sepers JM, van Diest PJ et al (2002) Atypical MEN type 2B associated with two germline RET mutations on the same allele not involving codon 918. J Clin Endocrinol Metab 87(1):393–397

    Article  CAS  PubMed  Google Scholar 

  • Milos IN, Frank-Raue K, Wohllk N, Maia AL, Pusiol E, Patocs A et al (2008) Age-related neoplastic risk profiles and penetrance estimations in multiple endocrine neoplasia type 2A caused by germ line RET Cys634Trp (TGC > TGG) mutation. Endocr Relat Cancer 15(4):1035–1041

    Article  CAS  PubMed  Google Scholar 

  • Miyauchi A, Futami H, Hai N, Yokozawa T, Kuma K, Aoki N et al (1999) Two germline missense mutations at codons 804 and 806 of the RET proto-oncogene in the same allele in a patient with multiple endocrine neoplasia type 2B without codon 918 mutation. Jpn J Cancer Res Gann 90(1):1–5

    Article  CAS  PubMed  Google Scholar 

  • Mulligan LM, Kwok JB, Healey CS et al (1993) Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 363:458–460

    Article  CAS  PubMed  Google Scholar 

  • Oliveira MN, Hemerly JP, Bastos AU, Tamanaha R, Latini FR, Camacho CP et al (2011) The RET p.G533C mutation confers predisposition to multiple endocrine neoplasia type 2A in a Brazilian kindred and is able to induce a malignant phenotype in vitro and in vivo. Thyroid 21(9):975–985 (official journal of the American Thyroid Association)

    Google Scholar 

  • Pacak K, Eisenhofer G, Ilias I (2009) Diagnosis of pheochromocytoma with special emphasis on MEN2 syndrome. Hormones 8(2):111–116

    Article  PubMed  Google Scholar 

  • Peppa M, Boutati E, Kamakari S, Pikounis V, Peros G, Panayiotides IG et al (2008) Multiple endocrine neoplasia type 2A in two families with the familial medullary thyroid carcinoma associated G533C mutation of the RET proto-oncogene. Eur J Endocrinol Eur Fed Endocr Soc 159(6):767–771

    Article  CAS  Google Scholar 

  • Quayle FJ, Fialkowski EA, Benveniste R, Moley JF (2007) Pheochromocytoma penetrance varies by RET mutation in MEN 2A. Surgery 142(6):800–805 discussion 5 e1

    Article  PubMed  Google Scholar 

  • Raue F, Frank-Raue K (2012) Genotype-phenotype correlation in multiple endocrine neoplasia type 2. Clinics 67(Suppl 1):69–75

    Article  PubMed Central  PubMed  Google Scholar 

  • Raue F, Kraimps JL, Dralle H, Cougard P, Proye C, Frilling A et al (1995) Primary hyperparathyroidism in multiple endocrine neoplasia type 2A. J Intern Med 238(4):369–373

    Article  CAS  PubMed  Google Scholar 

  • Rich TA, Feng L, Busaidy N, Cote GJ, Gagel RF, Hu M et al (2014) Prevalence by age and predictors of medullary thyroid cancer in patients with lower risk germline RET proto-oncogene mutations. Thyroid 24(7):1096–1106 (official journal of the American Thyroid Association)

    Google Scholar 

  • Rohmer V, Vidal-Trecan G, Bourdelot A, Niccoli P, Murat A, Wemeau JL et al (2011) Prognostic factors of disease-free survival after thyroidectomy in 170 young patients with a RET germline mutation: a multicenter study of the Groupe Francais d’Etude des Tumeurs Endocrines. J Clin Endocrinol Metab 96(3):E509–E518

    Article  CAS  PubMed  Google Scholar 

  • Romei C, Elisei R, Pinchera A, Ceccherini I, Molinaro E, Mancusi F et al (1996) Somatic mutations of the ret protooncogene in sporadic medullary thyroid carcinoma are not restricted to exon 16 and are associated with tumor recurrence. J Clin Endocrinol Metab 81(4):1619–1622

    CAS  PubMed  Google Scholar 

  • Romei C, Ugolini C, Cosci B, Torregrossa L, Vivaldi A, Ciampi R et al (2012) Low prevalence of the somatic M918t RET mutation in micro-medullary thyroid cancer. Thyroid 22: 476–481 (official journal of the American Thyroid Association)

    Google Scholar 

  • Rothberg AE, Raymond VM, Gruber SB, Sisson J (2009) Familial medullary thyroid carcinoma associated with cutaneous lichen amyloidosis. Thyroid 19(6):651–655 (official journal of the American Thyroid Association)

    Google Scholar 

  • Santoro M, Carlomagno F, Romano A, Bottaro DP, Dathan NA, Grieco M et al (1995) Activation of RET as a dominant transforming gene by germline mutations of MEN2A and MEN2B. Science 267(5196):381–383

    Article  CAS  PubMed  Google Scholar 

  • Sarika HL, Papathoma A, Garofalaki M, Vasileiou V, Vlassopoulou B, Anastasiou E et al (2012) High prevalence of exon 8 G533C mutation in apparently sporadic medullary thyroid carcinoma in Greece. Clin Endocrinol 77(6):857–862

    Article  CAS  Google Scholar 

  • Schilling T, Burck J, Sinn HP, Clemens A, Otto HF, Hoppner W et al (2001) Prognostic value of codon 918 (ATG→ACG) RET proto-oncogene mutations in sporadic medullary thyroid carcinoma. Int J Cancer J Int du Cancer 95(1):62–66

    Article  CAS  Google Scholar 

  • Scholten A, Valk GD, Ulfman D, Borel RIH, Vriens MR (2011) Unilateral subtotal adrenalectomy for pheochromocytoma in multiple endocrine neoplasia type 2 patients: a feasible surgical strategy. Ann Surg 254(6):1022–1027

    Article  PubMed  Google Scholar 

  • Schuffenecker I, Virally-Monod M, Brohet R, Goldgar D, Conte-Devolx B, Leclerc L et al (1998) Risk and penetrance of primary hyperparathyroidism in multiple endocrine neoplasia type 2A families with mutations at codon 634 of the RET proto-oncogene. Groupe D’etude des Tumeurs a Calcitonine. J Clin Endocrinol Metab 83(2):487–491

    CAS  PubMed  Google Scholar 

  • Shankar RK, Rutter MJ, Chernausek SD, Samuels PJ, Mo JQ, Rutter MM (2012) Medullary thyroid cancer in a 9-week-old infant with familial MEN 2B: Implications for timing of prophylactic thyroidectomy. Int J Pediatr Endocrinol 2012(1):25

    Article  PubMed Central  PubMed  Google Scholar 

  • Smith DP, Houghton C, Ponder BA (1997) Germline mutation of RET codon 883 in two cases of de novo MEN 2B. Oncogene 15(10):1213–1217

    Article  CAS  PubMed  Google Scholar 

  • Taieb D, Kebebew E, Castinetti F, Chen CC, Henry JF, Pacak K (2014) Diagnosis and preoperative imaging of multiple endocrine neoplasia type 2: current status and future directions. Clin Endocrinol 81(3):317–328

    Article  CAS  Google Scholar 

  • Takahashi M, Asai N, Iwashita T, Murakami H, Ito S (1998) Molecular mechanisms of development of multiple endocrine neoplasia 2 by RET mutations. J Intern Med 243(6):509–513

    CAS  PubMed  Google Scholar 

  • Toledo RA, Hatakana R, Lourenco DM Jr, Lindsey SC, Camacho CP, Almeida M et al (2015) Comprehensive assessment of the disputed RET Y791F variant shows no association with medullary thyroid carcinoma susceptibility. Endocr Relat Cancer 22(1):65–76

    Article  PubMed Central  CAS  PubMed  Google Scholar 

  • Vaclavikova E, Dvorakova S, Sykorova V, Bilek R, Dvorakova K, Vlcek P et al (2009) RET mutation Tyr791Phe: the genetic cause of different diseases derived from neural crest. Endocrine 36(3):419–424

    Article  CAS  PubMed  Google Scholar 

  • Verga U, Fugazzola L, Cambiaghi S, Pritelli C, Alessi E, Cortelazzi D et al (2003) Frequent association between MEN 2A and cutaneous lichen amyloidosis. Clin Endocrinol 59(2):156–161

    Article  CAS  Google Scholar 

  • Verga U, Morpurgo PS, Vaghi I, Radetti G, Beck-Peccoz P (2006) Normal range of calcitonin in children measured by a chemiluminescent two-site immunometric assay. Horm Res 66(1):17–20

    Article  CAS  PubMed  Google Scholar 

  • Wells SA Jr, Pacini F, Robinson BG, Santoro M (2013) Multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma: an update. J. Clin. Endocrinol Metab 98(8):3149–3164

    Article  CAS  PubMed  Google Scholar 

  • Wells SAA, S.L.; Dralle H, Elisei R, Evans DB, Gagel RF, Lee N, Machens A, Moley JF, Pacini F, Raue F, Frank-Raue K, Robinson B, Rosenthal SM, Santoro M, Schlumberger M, Shah M, Waguespack S (2015) Revised American Thyroid Association Guidelines for the Management of Medullary Thyroid Carcinoma. Thyroid: official journal of the American Thyroid Association 25(6):567–610 

    Google Scholar 

  • Zedenius J, Wallin G, Hamberger B, Nordenskjold M, Weber G, Larsson C (1994) Somatic and MEN 2A de novo mutations identified in the RET proto-oncogene by screening of sporadic MTC:s. Hum Mol Genet 3(8):1259–1262

    Article  CAS  PubMed  Google Scholar 

  • Zenaty D, Aigrain Y, Peuchmaur M, Philippe-Chomette P, Baumann C, Cornelis F et al (2009) Medullary thyroid carcinoma identified within the first year of life in children with hereditary multiple endocrine neoplasia type 2A (codon 634) and 2B. Eur J Endocrinol Eur Fed Endocr Soc 160(5):807–813

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Endokrinologische Gemeinschaftspraxis, Brückenstr 21, 69120, Heidelberg, Germany

    Karin Frank-Raue & Friedhelm Raue

Authors
  1. Karin Frank-Raue
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Friedhelm Raue
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Karin Frank-Raue .

Editor information

Editors and Affiliations

  1. Endocrine Practice and Molecular Laboratory, Medical Faculty, University of Heidelberg , Heidelberg, Germany

    Friedhelm Raue

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Frank-Raue, K., Raue, F. (2015). Hereditary Medullary Thyroid Cancer Genotype–Phenotype Correlation. In: Raue, F. (eds) Medullary Thyroid Carcinoma. Recent Results in Cancer Research, vol 204. Springer, Cham. https://doi.org/10.1007/978-3-319-22542-5_6

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-22542-5_6

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-22541-8

  • Online ISBN: 978-3-319-22542-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation